Confocal immunofluorescent analysis of HT-29 cells, transfected with SignalSilence® Control siRNA (Unconjugated) #6568 (left), SignalSilence® cdc2 siRNA I #3500 (center) or SignalSilence® cdc2 siRNA II #3600 (right), using cdc2 (POH1) Mouse mAb (green). Blue pseudocolor = DRAQ5® #4084 (fluorescent DNA dye).
Flow cytometric analysis of Jurkat cells, using CDK2 (78B2) Rabbit mAb versus propidium iodide (DNA content).
Flow cytometric analysis of Jurkat cells using CDK4 (D9G3E) Rabbit mAb and Propidium Iodid (PI)/RNase Staining Solution #4087 to measure DNA content. Anti-rabbit IgG (H+L), F(ab')2 Fragment (Alexa Fluor® 488 Conjugate) #4412 was used as a secondary antibody.
Immunoprecipitation of CDK6 from HeLa cell extracts using Rabbit (DA1E) mAb IgG XP® Isotype Control #3900 (lane 2) or CDK6 (D4S8S) Rabbit mAb (lane 3). Lane 1 is 10% input. Western blot was performed using CDK6 (DCS83) Mouse mAb #3136.
Immunohistochemical analysis of paraffin-embedded human breast carcinoma, showing nuclear localization, using CDK7 (MO1) Mouse mAb.
Flow cytometric analysis of Jurkat cells using CDK9 (C12F7) Rabbit mAb (blue) compared to a nonspecific negative control antibody (red).
After the primary antibody is bound to the target protein, a complex with HRP-linked secondary antibody is formed. The LumiGLO* is added and emits light during enzyme catalyzed decomposition.
Western blot analysis of extracts from HeLa cells synchronized at various stages of the cell cycle, using cdc2 (POH1) Mouse mAb.
Western blot analysis of extracts from HeLa, NIH/3T3, C6 and COS cells, using CDK2 (78B2) Rabbit mAb.
Confocal immunofluorescent analysis of MCF7 cells using CDK4 (D9G3E) Rabbit mAb (green), p21 Waf1/Cip1 (12D1) Rabbit mAb (Alexa Fluor® 555 Conjugate) #8493 (red), and Phospho-Histone H3 (Ser10) (D2C8) XP® Rabbit mAb (Alexa Fluor® 647 Conjugate) #3458 (blue pseudocolor).
Western blot analysis of extracts from HeLa, Jurkat, and COS-7 cells using CDK6 (D4S8S) Rabbit mAb.
Western blot analysis of extracts from SK-N-MC and C6 cells, using CDK7 (MO1) Mouse mAb.
Confocal immunofluorescent analysis of HeLa cells using CDK9 (C12F7) Rabbit mAb (green). Actin filaments have been labeled with DY-555 phalloidin (red).
Immunohistochemical analysis of paraffin-embedded human breast carcinoma using CDK4 (D9G3E) Rabbit mAb.
Immunohistochemical analysis of frozen SKOV-3 xenograft using CDK9 (C12F7) Rabbit mAb.
Immunohistochemical analysis of paraffin-embedded human lung carcinoma using CDK4 (D9G3E) Rabbit mAb in the presence of control peptide (left) or antigen-specific peptide (right).
Immunohistochemical analysis of paraffin-embedded human breast carcinoma using CDK9 (C12F7) Rabbit mAb in the presence of control peptide (left) or antigen specific peptide (right).
Western blot analysis of extracts from various cell lines using CDK4 (D9G3E) Rabbit mAb.
Immunohistochemical analysis of paraffin-embedded K7M2 mouse syngeneic tumor using CDK9 (C12F7) Rabbit mAb.
Immunoprecipitation of CDK9 from HeLa cells using CDK9 (C12F7) Rabbit mAb. Western blot detection was performed using the same antibody. Lane 1 is 5% input.
Western blot analysis of extracts from various cell types using CDK9 (C12F7) Rabbit mAb.
|cdc2 (POH1) Mouse mAb 9116||20 µl||
||H Mk||34||Mouse IgG2a|
|CDK2 (78B2) Rabbit mAb 2546||20 µl||
||H M R Mk||33||Rabbit|
|CDK4 (D9G3E) Rabbit mAb 12790||20 µl||
||H Mk||30||Rabbit IgG|
|CDK6 (D4S8S) Rabbit mAb 13331||20 µl||
||H Mk||36||Rabbit IgG|
|CDK7 (MO1) Mouse mAb 2916||20 µl||
||H R||40||Mouse IgG2b|
|CDK9 (C12F7) Rabbit mAb 2316||20 µl||
||H M R Hm Mk B Dg||42, 55||Rabbit|
|Anti-rabbit IgG, HRP-linked Antibody 7074||100 µl||
|Anti-mouse IgG, HRP-linked Antibody 7076||100 µl||
The CDK Antbody Sampler Kit provides and economical means of evaluating Cdk proteins. The kit contains enough primary and secondary antibodies to perform two western blot experiments.
Each antibody in the CDK Antibody Sampler Kit detects endogenous levels of its respective target protein and does not cross-react with other family members.
Monoclonal antibody is produced by immunizing animals with a recombinant human cdc2 fusion protein, synthetic peptides corresponding to residues of human CDK2 and recombinant human CDK7, and residues near the carboxy terminus of human CDK4, human CDK6, and human CDK9 proteins.
Cyclin-dependent kinases (CDKs) are the core effectors of cell cycle progression. CDK activity is regulated through association with their cyclin partners and cyclin-dependent kinase inhibitors (CKIs) as well as by activating and inhibitory phosphorylation events. Inhibition is mediated by Wee1 and Myt1 kinases that target residues at the amino terminus of CDK1 (1,2). Dephosphorylation of these residues by cdc25 phosphatase leads to activation of CDK kinase activity (3). The CDK7/cyclinH complex is the ubiquitous mammalian CDK-activating kinase (CAK) that phosphorylates a conserved threonine residue in the T-loop domain of CDKs. The carboxy-terminal domain of RNA polymerase II is also a target of CAK as well as CDK9/cyclinT (4,5). CDK4/6 associate with cyclinD and phosphorylate retinoblastoma protein and initiate progression through the restriction point in G1 (6). CDK2 associates with cyclinE in early S phase and cyclinA later in G2. CDK1/cyclinB regulates the initiation of mitotic events (7).
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
U.S. Patent No. 7,429,487, foreign equivalents, and child patents deriving therefrom.